Total thyroidectomy followed by postsurgical remnant ablation may improve cancer specific survival in differentiated thyroid carcinoma

Clinical Nuclear Medicine

Volumn 35, Issue 6, 2010, Pages 396-399

  Doi, Suhail A R ^a   Engel, Jessica M ^b   Onitilo, Adedayo A ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b MARSHFIELD CLINIC   (United States)

Author keywords

Cancer specific survival; Differentiated thyroid cancer; Radioiodine ablation; Thyroidectomy

Indexed keywords

RADIOACTIVE IODINE;

ADULT; ARTICLE; CANCER MORTALITY; CANCER STAGING; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; SUBTOTAL THYROIDECTOMY; SURVIVAL RATE; THYROID CARCINOMA; THYROIDECTOMY; TUMOR ABLATION;

ABLATION TECHNIQUES; CELL DIFFERENTIATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; REGRESSION ANALYSIS; RISK; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 77952524906     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e3181db4db4     Document Type: Article

References (28)

1. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma: a study of the E. O. R. T. C. Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033-1041.
2. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947-953.
3. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-424.
4. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1057.
5. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428.
6. Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of thyroid. Surgery. 1994;116:1036-1040.
7. Lerch H, Schober O, Kuwert T, et al. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol. 1997;15:2067-2075.
8. Beenken S, Roye D, Weiss H, et al. Extent of surgery for intermediate-risk well-differentiated thyroid cancer. Am J Surg. 2000;179:51-56.
9. Sosa JA, Udelsman R. Total thyroidectomy for differentiated thyroid cancer. J Surg Oncol. 2006;94:701-707.
10. Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375-381.
11. Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1463.
12. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab. 1992;75:714-720.
13. Loh KC, Greenspan FS, Gee L, et al. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. J Clin Endocrinol Metab. 1997;82:3553-3562.
14. Podnos YD, Smith DD, Wagman LD, et al. Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope. J Surg Oncol. 2007;96:3-7.
15. Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys. 1988;14:1063-1075.
16. Tubiana M, Schlumberger M, Rougier P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer. 1985;55:794-804. (Pubitemid 15173518)
17. Sanders LE, Cady B. Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. Arch Surg. 1998;133:419-425. (Pubitemid 28193527)
18. Mazzaferri EL. Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. Thyroid. 1997;7:265-271.
19. Hay ID. Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma. J Surg Oncol. 2006;94:692-700.
20. Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: a systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89:3668-3676.
21. Greenlee RT. Measuring disease frequency in the Marshfield Epidemiologic Study Area (MESA). Clin Med Res. 2003;1:273-280.
22. Wilke RA, Berg RL, Peissig P, et al. Use of an electronic medical record for the identification of research subjects with diabetes mellitus. Clin Med Res. 2007;5:1-7.
23. Onitilo AA, Engel JM, Lundgren CI, et al. Simplifying the TNM system for clinical use in differentiated thyroid cancer. J Clin Oncol. 2009;27:1872-1878.
24. Ramirez AT, Gibelli B, Tradati N, et al. Surgical management of thyroid cancer. Expert Rev Anticancer Ther. 2007;7:1203-1214.
25. Haigh PI, Urbach DR, Rotstein LE. Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer. Ann Surg Oncol. 2005;12:81-89.
26. Lin JD, Chao TC, Chen ST, et al. Operative strategy for follicular thyroid cancer in risk groups stratified by pTNM staging. Surg Oncol. 2007;16:107-113.
27. Mazzaferri EL. Management of low-risk differentiated thyroid cancer. En-docr Pract. 2007;13:498-512.
28. Verburg FA, de Keizer B, Lips CJ, et al. Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. Eur J Endocrinol. 2005;152:33-37.